ArticleHaematologica2024
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients.
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Prognostic value of echocardiography in light chain cardiac amyloidosis: after adjusting for treatment status.Quantitative imaging in medicine and surgery · 2026Article
- Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging.European heart journal. Imaging methods and practice · 2026Review
- Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens.Blood advances · 2025Article
- Recent developments in systemic light-chain amyloidosis prognosis and treatment.Future cardiology · 2025Review
- Pseudoinfarction Q Waves From a Stiff Heart: Classic But Commonly Overlooked Presentation of Cardiac Amyloidosis.JACC. Case reports · 2025Article
- Development and validation of an early prediction model for cardiac death risk in patients with light chain amyloidosis: a multicenter study.Cardio-oncology (London, England) · 2025Article
- A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.Bone marrow transplantation · 2025Article
- Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis.British journal of haematology · 2025Article
- A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.Cancers · 2024Article
- Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.